Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICORYX-2: P16_37-63 Peptide Vaccine with Chemotherapy in HPV+ Cancers
NCT02526316Phase 1Completed
- Start
- Jun 2015
- Primary completion
- May 2017
- Modality
- Peptides, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of P16_37-63 peptide in Cervical Cancer (CC), vulvar cancer, vaginal cancer and 3 more. Primary endpoint: Immune response against peptide P16_37-63 at 25 weeks. Started Jun 2015; status: completed.
02
Drugs
P16_37-63 peptide
03
Conditions
Cervical Cancer (CC)vulvar cancervaginal cancerpenile canceranal cancer
Beyond the preview
Go deeper on NCT02526316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02526316.